Company intelligence / Profile preview

Emotional Brain

Almere, Flevoland, Netherlandsebtconnect.net ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Positive phase 2b results published in the Journal of Sexual Medicine showed that both Lybrido and Lybridos significantly improved sexual satisfaction in women with FSIAD compared to placebo, with a favorable safety profile and no significant side effects. The compounds met primary endpoints in a multicenter US-based trial involving nearly 500 women. Further development toward phase 3 was planned by the acquiring company.

Therapeutic areas: Women's Health
Modalities: Small moleculeCombination therapy
Industry: Biotech

Drug pipeline

1 asset

Lybrido

Unknown

Partnerships

None publicly disclosed prior to acquisition; post-acquisition partnerships would be under Freya Pharma Solutions.

Beyond the preview

Go deeper on Emotional Brain.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emotional Brain.

Explore the full profile